Comparison of the action of associated antigens and associated inactivated cells of c. Albicans and c. Tropicalis fungi
Keywords:candidiasis, antigen, vaccine, immunity, therapy
Many researchers believe that the use of drugs that can stimulate protective immune responses against candidal infections, i.e. immunobiological drugs stimulating the protective function, is promising in the fight against candidiasis. The aim of this work was to compare protective and therapeutic properties of the associated antigens and the associated inactivated cells of C. albicans and C. tropicalis fungi. The protective and therapeutic effects of the associated inactivated suspension of C. albicans and C. tropicalis fungi with the concentration of 10 + 10 (mln.c/ml) and the associated antigens of C. albicans fungi with the protein concentration of 3 mg/ml, and C. tropicalis with the protein concentration of 5 mg/ml in the ratio of 1:1 were compared. The research was carried out in healthy two month white mice weighing 18-22 g; there were six animals in the control and experimental groups each. As the result of the studies, it has been found that the use of the combined antigens of C. albicans and C. tropicalis provides 100% protective and therapeutic effects in mice. The inactivated suspension of C. albicans and C. tropicalis fungi provides 84% protective and therapeutic effect in mice for 3 months after intramuscular injection of 0.2 ml. In 16% of animals treated with the inactivated suspension of fungi the signs of a mild disease have been revealed. In future it is planned to substantiate experimentally the type and concentration of excipients such as preservatives, stabilizers and adjuvants in the composition of the solution of the associated antigens of C. albicans and C. tropicalis fungal cells.
Голубка О.В. // Annals of Mechnikov Institute. – 2011. – №2. – С. 51-59.
Жукова Н.В., Кривошеева И.М. // Кримський терапевт. журн. – 2013. – №2. – С. 99-104.
Carvalho A., Cunha C., Iannitti R.G. et al. // Front. Microbiol. – 2012. – Vol. 3. – P. 1-9.
Cassone A. // Lancet Infect. Dis. – 2008. – Vol. 8. – P. 114-124.
D’Argenio D.A., Wilson C.B. // Immunity. – 2010. – Vol. 33, №4. –P. 437-440.
Grover A., Bhandari B.S., Rai N., Lakhera P.C. // Biotechnol. International. – 2010. – Vol. 3, №1. – P. 4-17.
Han Y., Rhew K.Y. // Arch. Pharm. Res. – 2012. – №35. – P. 2021-2027.
LeibundGut-Landman S., Wutrich M., Hohl T. // Curr. Opin. Immunol. – 2012. – Vol. 24. – P. 1-10.
Nabel G.J. // N. Eng. J. Med. – 2013. – Vol. 6, №368. –Р. 551-60.
Petrov P.V., Khaitov R.M. Immunogens and New Generation Vaccine. – M.: GEOSTAR-Medicine, 2011. – 608 p.
Skibinski A.G.D., Baudner C.B., Manmohan S. et al. // Glob. Infect. Dis. – 2011. – Vol. 3, №1. –P. 63-72.
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).